P2 nucleotide receptors on C2C12 satellite cells

Witk tor Banachewicz, Dorota Supłat, Patryk Krzemiński, Paweł Pomorski & Jolanta Barańska
Department of Molecular and Cellular Neurobiology, Nencki Institute of Experimental Biology, Polish Academy of Sciences, Warsaw, Poland

Received 12 October 2004; accepted in revised form 7 March 2005

Key words: C2C12 myoblasts and myotubes, Ca^{2+} response, ERK1/2 activity, P2X and P2Y receptors

Abstract
In developing muscle cells environmental stimuli transmitted by purines binding to the specific receptors are crucial proliferation regulators. C2C12 myoblasts express numerous purinergic receptors representing both main classes: P2X and P2Y. Among P2Y receptors we have found the expression of P2Y_1, P2Y_2, P2Y_4, P2Y_6 and P2Y_12 family members while among P2X receptors P2X_4, P2X_5 and P2X_7 were discovered. We have been able to show that activation of those receptors is responsible for ERK class kinase activity, responsible for regulation of cell proliferation pathway. We have also demonstrated that this activity is calcium dependent suggesting Ca^{2+} ions as secondary messenger between receptor and kinase regulatory system. More specifically, we do suspect that in C2C12 myoblasts calcium channels of P2X receptors, particularly P2X_5 play the main role in proliferation regulation. In further development of myoblasts into myotubes, when proliferation is gradually inhibited, the pattern of P2 receptors is changed. This phenomenon is followed by diminishing of the P2Y_2-dependent Ca^{2+} signaling, while the mRNA expression of P2Y_2 receptor remains still on the high level. Moreover, P2X_2 receptor mRNA, absent in myoblasts appears in myotubes. These data show that differentiation of C2C12 cell line satellite myoblasts is accompanied by changes in P2 receptors expression pattern.

Abbreviations: 2MeSADP – 2-methylthio-ADP; BzATP – 3′-(4-benzoyl)benzoyl ATP; [Ca^{2+}]_i – intracellular Ca^{2+} concentration; DMEM – Dulbecco’s modified essential medium; ERK – Ras/extracellular signal-regulated kinase; FCS – fetal calf serum; GAPDH – glycerol 3-phosphate dehydrogenase; HS – horse serum; InsP_3 – inositol 1,4,5-trisphosphate; PLC – phospholipase C; PPADS – pyridoxal-phosphate-6-azophenyl-2,4′-disulphonic acid

Introduction
Skeletal muscle satellite cells are precursors of mammalian skeletal muscle multinucleated myotubes. The small population of these satellite cells posses in vivo a special ability to respond to myofibers damage. After muscle fiber injury, satellite cells are activated, start to proliferate, become committed to differentiation and fuse to form new myotubes [1–4]. Similar process of myotubes formation can be observed in vitro using primary culture of satellite cells [4–6], or satellite myoblast cell cultures [7].

Differentiation of muscle cells is regulated by extracellular growth factors that transmit signals into the cells [3]. Functional studies on satellite cells have shown that MAPK activity is involved in directing myogenesis [8–10]. Extracellular ATP acting trough P2X and P2Y purinergic receptors is also involved in this process [5, 11–13]. P2X_1–3 receptors are intrinsic ligand-gated ion channels and activation of these receptors by ATP evokes a flow of cations (Na^+, K^+ and Ca^{2+}) across the plasma membrane. P2Y receptors are G-protein coupled receptors linked to activation of phospholipase C (PLC), inositol lipid signaling and the mobilization of intracellular Ca^{2+} (for review see: [14–17]). Within the family of P2Y receptors P2Y_1 responds selectively to ADP, 2-methylthio-ADP (2MeSADP) is also a selective agonist of high potency for this receptor, while UTP is not effective. In contrast, P2Y_2 receptor responds to ATP and UTP, while 2MeSADP has no effect on its activation. P2Y_4 receptor responds to UTP and P2Y_4 to UDP. In the case of P2Y_12 and P2Y_13 receptors responding to ADP, their coupling to G_i protein results in inhibition of cAMP formation [16, 18–20].

It is well established that ATP has potent effects on developing skeletal muscle. These effects are developmentally regulated and those responses have been shown to be characteristic for activation of the P2X purinergic receptors [11]. More recently, the expression of specific P2X receptor subtypes during skeletal muscle development [5, 11, 13] and in regenerating skeletal muscles [4] have been demonstrated. Among these receptors, P2X_4 and P2X_6, and P2X_2 and P2X_5, have been found to be expressed in chick and rat skeletal muscle development, respectively [5, 11].
On the contrary, the expression and function of P2Y nucleotide receptors in developing skeletal muscle cells has rarely been studied. In chick muscle, the P2Y₁ receptor was implicated in the regulation of acetylcholine receptor [21]. The expression of this receptor was detected during the first 10 days of chick embryonic development [12]. In rat embryonic skeletal muscle cells, Cheung et al. [22] found similar early expression of the P2Y₁ receptor, whereas the P2Y₂ receptor expression became progressively stronger with development and the P2Y₄ receptor expression was similarly high at early and late embryonic days. In contrast, postnatal skeletal muscles from 3-week- or 2-month-old rats demonstrated the down-regulation of P2Y₄ receptor expression and P2Y₁ as well as P2Y₂ receptor expression were detected only in the small population of cells present between muscle fibers, tentatively identified as satellite cells [22].

In this study, using RT-PCR analysis we investigated the presence of P2Y and P2X receptors on cultured mouse satellite C2C12 cells and their involvement in ERK1/2 activation and intracellular Ca²⁺ mobilization. We compared the mRNA expression levels of P2Y₁, P2Y₂, P2Y₄, P2Y₆, P2Y₁₂ and P2X₁, -₇ receptors in C2C12 myoblasts and myotubes and demonstrated that in myotubes the expression of all P2Y receptors mRNA decreased, except of P2Y₂, P2X₄, P2X₅ and P2X₇ receptors are present both in myoblast and myotubes while receptor P2X₅ mRNA appears only in myotubes. We suspect that nucleotide can regulate myoblast proliferation and differentiation via both P2X and P2Y receptors, and particularly the ATP-responding P2X₅ and P2Y₂ receptor seem to be involved in these processes.

Materials and methods

Materials

Dulbecco’s modified essential medium (DMEM), fetal calf serum (FCS), horse serum (HS) was from Gibco BRL. TRI reagent, ADP, ATP, UTP, UDP, 2MeSADP, BzATP, BSA, EGTA, Trypsin-EDTA solution, phosphate-buffered solution (PBS), ethidium bromide, agarose and common chemicals were purchased from Sigma Chemical Co. Penicillin was from Polfa Tarchomin Poland, Fura-2/AM was from Molecular Probes, Inc. Pyridoxal-phosphate-6-azophenyl-2, 4’-disulfonic acid (PPADS) was obtained from Research Biochemicals International. Expand RT enzyme was purchased from Roche. Taq PCR Core Kit was obtained from QIAGEN and M-MLV Reverse Transcriptase from Sigma Chemical Co.

Cell culture

C2C12 cells, a murine myoblast cell line was from the American Tissue Culture Collection, Rockville, USA, (ATCC) and was a kind gift from Prof Jerzy Moraczewski, Warsaw University, Warsaw, Poland. Cells were cultured in DMEM with high glucose (4500 g dm⁻³) and Glutamax I, supplemented with 10% (v/v⁻¹) FCS and penicillin (100 UI ml⁻¹) under humidified atmosphere of 5% CO₂ at 37 °C. The cells were passaged when reached state of about 60% confluence, and medium was changed three times a week. For experiments, cells were cultivated in DMEM supplemented with 10% FCS to reach 80% confluence: in 60-mm dishes (for Western blot analysis), in 100-mm dishes (for RT-PCR analysis), on 24-mm glass coverslips in 35-mm dishes (for calcium measurement). Medium was changed 12 h before each experiment. In case of calcium measurements, 30 min before the experiment, cells were washed once with PBS and once with the solution containing: 137 mM NaCl, 2.7 mM KCl, 1-mM Na₂HPO₄, 25 mM glucose, 20 mM HEPES (pH 7.4). Later referred as standard buffer. Only in experiments performed in the absence of external Ca²⁺, 500 μM EGTA was added instead of 2 mM CaCl₂. In case of differentiation myoblasts to myotubes, cells were grown to 90% confluence and medium was changed DMEM supplemented with 2% HS, which was changed third and fifth day of culture. Myotubes were harvested for experiments on fifth and seventh day of differentiation.

Measurement of intracellular calcium Cells on coverslips were washed once with PBS and once with the standard buffer. The cells were incubated at 37 °C for 30 min in the standard buffer with 1 μM Fura-2 AM. Thereafter, the coverslips were mounted in a chamber over a Nikon Diaphot inverted-stage microscope equipped with a fluo × 40/1.3 NA oil-immersion objective lens. Fura-2 digital fluorescence microscopy was used to determine the changes in intracellular calcium levels ([Ca²⁺]i) [23]. Ludl Lep MAC 5000 filter wheel system loaded with Chroma Inc. Fura-2 filter set was used for illumination of specimens. Images were acquired using Retiga 1300 chilled digital CCD camera (QImaging Inc.). Data processing was carried out using AQM Advance 6 (Kinetic Imaging Inc) and MS Excel software.

Preparation of cell extracts and Western blot analysis of phospho-ERK1 and ERK2

For these experiments cells were plated in 60-mm dishes and were incubated with agonists in DMEM medium at 37 °C for various times. When antagonists were used, they were applied 2 min prior to the addition of agonists. The reaction was stopped by aspiration of the medium, washing once with ice-cold PBS and addition of lysis buffer: 50-mM Tris/HCl pH 7.5, 1% (v/v⁻¹) Nonident NP-40, 120-mM NaCl, 25-mM NaF, 40-mM β-glycerol phosphate, 0.1-mM Na₃VO₄, 1-mM phenyl methyl sulfon-yl fluoride (PMSF), 1-mM benzamidine. Cell extracts were then centrifuged 12,000 g for 30 min at 4 °C and supernatants were transferred to new tubes. Protein concentration was measured by Bradford method [24]. Then samples were mixed with 4 times concentrated Laemmli sample buffer: 200-mM Tris/HCl pH 6.8, 2% (v/v⁻¹) SDS,
Detection of P2Y receptors mRNA and RT-PCR analysis

Total RNA was extracted using TRI reagent. Reverse transcription of total RNA was performed using Expand RT enzyme. Specific primers for PCR reaction were designed using ‘Primer 3’ software. All primers were based on unique sequences comprising bases in case of: P2Y1 (1100-1123) 5' GTG GCC TGG TGT ACC CTC TCA AGT 3' (forward), (1666-1650) 5' TGG TGG TGC CTC GGG ACA GT 3' (backward), product length 566 bp (Acc. No. NM_008772); P2Y2 (229-250) 5' GCT GCC GGT GGC CTC ATG AAC T 3' (forward), (759-736) 5' CAC CCC GGG GTG AGT AAT AAA CCA 3' (backward), product length 530 bp (Acc. No. NM_007873); P2Y4 (549-572) 5' TGG CCA CCC TCC TCT ACT ATG 3' (forward), (1016-993) 5' GAG AAC GGA GCC GAG AAG ATG ACT 3' (backward), product length 468 bp (Acc. No. NM_02062); P2Y6 (161-177) 5' CCC GCC GGA CCC TCA CC 3' (forward), (652-633) 5' GGC GGG CCA TGC GAC AGT AG 3' (backward), product length 491 bp (Acc. No. AF298899); P2Y12 (342-362) 5' CTT TGC TGG GTT CAT CAC GAA 3' (forward), (744-721) 5' CTT ATC TTT TGG CCT CTT GTT GGT 3' (backward), product length 401 bp (Acc. No. NM_027571). As a reference control glycerol 3-phosphate dehydrogenase (GAPDH) was used. The estimated product length was 900 bp, unique sequence: (581-600) 5' ACC ACA GTG GGC ACC ATC AC 3' (forward), (1032-1013) 5' TCC ACC ACC CTG TTG CTG TA 3' (backward) (Acc. No. BC083149). Equal amounts of cDNA were used in parallel experiments. A hot-start PCR protocol was used, involving denaturation at 95 °C, annealing at 60 °C (30 cycles), at 65.0 °C (GAPDH, 32 cycles). PCR products were separated on 2% agarose gel, stained with ethidium bromide and quantified using ImageQuant and MS Excel software.

Detection of P2X receptors mRNA and RT-PCR analysis

Total RNA was extracted using TRI reagent. Reverse transcription of total RNA was performed using M-MLV Reverse Transcriptase. Specific primers for PCR reaction were designed using ‘Primer 3’ software. All primers were based on unique sequences comprising bases in case of: P2X1 (927-946) 5' TGG TTG GTA TCA CCA TCG AC 3' (forward), (1009-1028) 5' CAG GTT CTG CTC CCC GTA CA 3' (backward), product length 101 bp (Acc. No. NM_153400); P2X2 (898-917) 5' CAA CAT TGC AAG CCA AAA GA 3' (forward), (1012-1032) 5' TTG TGT GCC AGT TGT AAG 3' (backward), product length 135 bp (Acc. No. NM_153400); P2X3 (762-781) 5' CTC TCC TAA CCT CAC CGA CA 3' (forward), (854-873) 5' TCG TTC CGA CCA AAC TTA AC 3' (backward), product length 111 bp (Acc. No. NM_145526); P2X4 (97-116) 5' GGC TTT CCT GTT CGA TGA CG 3' (forward), (186-205) 5' CCA ATG ACG TAA GCC AGG AT 3' (backward), product length 108 bp (Acc. No. NM_011026); P2X5 (210-233) 5' AGT GTG TTT GGT TGT GAA AAA AAC GAG G 3' (forward), (338-360) 5' TGA GCC ATG AAG CCA TTG TAT 3' (backward), product length 102 bp (Acc. No. NM_011028); P2X6 (127-146) 5' TTT GTC TTG GTG AGC GAT AA 3' (forward), (247-267) GGA AAG GTG TAG TGT CCA GTG 3' (backward), product length 161 bp (Acc. No. NM_011027). As a reference control glycerol 3-phosphate dehydrogenase (GAPDH) was used. The estimated product length was 800 bp, unique sequence: (581-600) 5' ACC ACA GTC CAT GCC TTC AC 3' (forward), (1032-1013) 5' CTC ACC ACC CTG TTG CTG TA 3' (backward) (Acc. No. BC083149). Equal amounts of cDNA were used in parallel experiments. A hot-start PCR protocol was used, involving denaturation at 95 °C, annealing at 60 °C (30 cycles), at 65.0 °C (GAPDH, 32 cycles). PCR products were separated on 2% agarose gel, stained with ethidium bromide.

Results

C2C12 myoblasts, a mouse satellite cell line, were differentiated to myotubes by transferring the cells from high (10% FCS) to low (2% HS) serum growth medium. The alterations in the morphology of myoblasts, differentiated to myotubes 7 days after changing the serum growth medium is presented in Figure 1 (Figures 1A and B, respectively).

In order to find out whether the differentiation of C2C12 cells may have an impact on the mRNA expression of P2Y and P2X receptors, the mRNA level of these receptors was measured using RT-PCR method. As a quantitative control mRNA of constitutively active GAPDH gene product was used. Figure 1 shows that all, P2Y1, P2Y2, P2Y4, P2Y6 and P2Y12 as well as P2X4, P2X5 and P2X7 receptors mRNA were expressed in both myoblasts and myotubes. In myoblasts, the mRNA expression of P2Y1, P2Y2 and P2Y4 receptors was strong, while P2Y6 and P2Y12 weak, and the
Figure 1. Seven days of C2C12 cells differentiation leads to changes in morphology from myoblast (A) to myotubes (B) as observed in light microscopy (DIC Nomarski). Morphological changes are accompanied by changes in P2Y (myoblasts – C and myotubes – D) and P2X (myoblasts – E and myotubes – F) mRNA receptors expression. GAPDH measured as constitutively active control. For details, see Materials and methods. Experiments were repeated four times.

Figure 2. Time-dependent activation of p44/42 ERK1/ERK2. C2C12 myoblasts were grown as described in Materials and methods. The cells were stimulated with specific purinergic receptor ligands (see legend) and ERK activation was measured by immunoblotting (lower panel) and quantified by densitometry (upper panel). Note, that ERK2 phosphorylation level is generally higher, while ERK1 phosphorylation shows stronger dynamics. Actin was used as a control. Experiments were conducted on three separate occasions. All measurements were made in three repetitions; error bars on the plot represent ±S.D. Concentration of used ligands: ATP 100 μM, ADP 10 μM, 2MeS ADP 10 μM, UTP 100 μM and UDP 100 μM.
strongest mRNA expression was found for P2Y2 receptor (Figure 1C). However, after myoblasts differentiation to myotubes, P2Y3 and P2Y12 (ADP sensitive), P2Y6 (UTP sensitive) and P2Y6 (UDP sensitive) mRNA expression was distinctly decreased (Figure 1D). Only the level of the ATP sensitive, P2Y2 receptor mRNA expression was not changed (Figure 1C versus D). In C2C12 cells mRNA for P2X4, P2X5, and P2X7 receptors was found both in myoblasts and myotubes. P2X2 mRNA was absent in myoblasts and appeared after 7 days of differentiation to myotubes (Figure 1E versus F).

To determine whether in myoblasts, P2Y receptors are involved in ERK1/2 activation, the cells were stimulated with ATP (100 μM), ADP (10 μM), 2MeSADP (10 μM), UTP (100 μM) and UDP (100 μM), and phosphorylation status of p44/Erk1 and p42/Erk2 was monitored by Western blot analysis. As shown in Figure 2, all nucleotides induced a transient increase in the level of p42 and p44 phosphorylation and in any case p42/ERK2 phosphorylation (also a basal level) was higher than that of p44/ERK1 (see Western blots). Densitometric analysis of the blots revealed that, within 5–15 min, these compounds induced the highest increase in the phosphorylation level. In comparison to the basal level, representing ERK1/2 phosphorylation in the absence of receptor agonists, changes in phosphorylation were more pronounced in ERK1 (Figure 2, left panel). Stimulation of cells with UDP produced the lowest phosphorylation level of ERKs. In the case of ATP, an additional peak of ERK1 phosphorylation, after 30 min of the cells stimulation was also observed (Figure 2, left panel). The effect of ATP may be explained by the activation of more than one, different P2 receptors.

To examine whether the effect of nucleotides on p44/p42 ERK1/ERK2 activation was Ca2+ dependent, myoblasts were placed in calcium-free medium and ERK1/ERK2 activity was measured by Western blot analysis. As shown in Figure 3, extracellular Ca2+ removal strongly inhibited ERK1/2 activation. These data pointed out the significant role of Ca2+ in ERK1/2 activation.

In the subsequent experiments influence of ATP on ERKs activation in C2C12 myotubes was examined. Figure 4A shows that ATP (100 μM) stimulated a rapid and transient increase in the phosphorylation level of the active ERK1/ ERK2 in myotubes. Stimulation with ATP reached the highest increase after 5 min. The second peak of ERK activation (characteristic for myoblasts) was not observed and after 30 min, ERK activation returned to the control level.

Since ATP can activate P2Y2 and P2X receptors, the cells (myoblasts as well as myotubes) were pretreated 2 min with 100 μM pyridoxal-5-phosphate-6-azophenyl-2′, 4′-disulfonic acid (PPADS) and then treated for 5 min with 100 μM ATP. PPADS is well known antagonist of P2X2 and P2X5 receptors, whereas P2X4 and P2Y2 are insensitive to this compound [14]. Figure 4B shows that preapplication of PPADS resulted in almost complete inhibition of ERKs activation in myoblasts, indicating the role of P2X receptors in this process. On the contrary to myoblasts, PPADS treatment of myotubes differentiated for 5 or 7 days (time after changing culture medium to differentiating medium) did not inhibit ATP-induced ERKs activation.
Myoblasts were placed in the medium containing 2-mM CaCl₂ (Figure 5A) or in Ca²⁺-free medium (Figure 5B). Figure 5A (solid line) shows that 100-µM ATP-induced Ca²⁺ elevation started only with an initial peak response. In the presence of PPADS (100 µM) (Figure 5A, dashed line), the level of control ERK phosphorylation are uncomparable between experimental setups.

The effect of ATP on intracellular Ca²⁺ mobilization in C2C12 myoblasts and myotubes is shown in Figure 5. Myoblasts were placed in the medium containing 2-mM CaCl₂ (Figure 5A) or in Ca²⁺-free medium (Figure 5B). Figure 5A (solid line) shows that 100-µM ATP-induced Ca²⁺ elevation started only with an initial peak response. In the presence of PPADS (100 µM) (Figure 5A, dashed line), the level of control ERK phosphorylation are uncomparable between experimental setups.

The effect of ATP on intracellular Ca²⁺ mobilization in C2C12 myoblasts and myotubes is shown in Figure 5. Myoblasts were placed in the medium containing 2-mM CaCl₂ (Figure 5A) or in Ca²⁺-free medium (Figure 5B). Figure 5A (solid line) shows that 100-µM ATP-induced Ca²⁺ elevation started only with an initial peak response. In the presence of PPADS (100 µM) (Figure 5A, dashed line), the level of control ERK phosphorylation are uncomparable between experimental setups.

The effect of ATP on intracellular Ca²⁺ mobilization in C2C12 myoblasts and myotubes is shown in Figure 5. Myoblasts were placed in the medium containing 2-mM CaCl₂ (Figure 5A) or in Ca²⁺-free medium (Figure 5B). Figure 5A (solid line) shows that 100-µM ATP-induced Ca²⁺ elevation started only with an initial peak response. In the presence of PPADS (100 µM) (Figure 5A, dashed line), the level of control ERK phosphorylation are uncomparable between experimental setups.

The effect of ATP on intracellular Ca²⁺ mobilization in C2C12 myoblasts and myotubes is shown in Figure 5. Myoblasts were placed in the medium containing 2-mM CaCl₂ (Figure 5A) or in Ca²⁺-free medium (Figure 5B). Figure 5A (solid line) shows that 100-µM ATP-induced Ca²⁺ elevation started only with an initial peak response. In the presence of PPADS (100 µM) (Figure 5A, dashed line), the level of control ERK phosphorylation are uncomparable between experimental setups.

The effect of ATP on intracellular Ca²⁺ mobilization in C2C12 myoblasts and myotubes is shown in Figure 5. Myoblasts were placed in the medium containing 2-mM CaCl₂ (Figure 5A) or in Ca²⁺-free medium (Figure 5B). Figure 5A (solid line) shows that 100-µM ATP-induced Ca²⁺ elevation started only with an initial peak response. In the presence of PPADS (100 µM) (Figure 5A, dashed line), the level of control ERK phosphorylation are uncomparable between experimental setups.

The effect of ATP on intracellular Ca²⁺ mobilization in C2C12 myoblasts and myotubes is shown in Figure 5. Myoblasts were placed in the medium containing 2-mM CaCl₂ (Figure 5A) or in Ca²⁺-free medium (Figure 5B). Figure 5A (solid line) shows that 100-µM ATP-induced Ca²⁺ elevation started only with an initial peak response. In the presence of PPADS (100 µM) (Figure 5A, dashed line), the level of control ERK phosphorylation are uncomparable between experimental setups.

The effect of ATP on intracellular Ca²⁺ mobilization in C2C12 myoblasts and myotubes is shown in Figure 5. Myoblasts were placed in the medium containing 2-mM CaCl₂ (Figure 5A) or in Ca²⁺-free medium (Figure 5B). Figure 5A (solid line) shows that 100-µM ATP-induced Ca²⁺ elevation started only with an initial peak response. In the presence of PPADS (100 µM) (Figure 5A, dashed line), the level of control ERK phosphorylation are uncomparable between experimental setups.

The effect of ATP on intracellular Ca²⁺ mobilization in C2C12 myoblasts and myotubes is shown in Figure 5. Myoblasts were placed in the medium containing 2-mM CaCl₂ (Figure 5A) or in Ca²⁺-free medium (Figure 5B). Figure 5A (solid line) shows that 100-µM ATP-induced Ca²⁺ elevation started only with an initial peak response. In the presence of PPADS (100 µM) (Figure 5A, dashed line), the level of control ERK phosphorylation are uncomparable between experimental setups.
the kinetic of ATP-evoked Ca\textsuperscript{2+} changes differed from those observed without addition of this compound. In the presence of PPADS, ATP initiated Ca\textsuperscript{2+} response much weaker and biphasic, consistent with the PLC-mediated Ca\textsuperscript{2+} release from the endoplasmic reticulum Ca\textsuperscript{2+} stores (the first phase of calcium response) and capacitative Ca\textsuperscript{2+} enter from the extracellular space (the second phase). Such response is typical for metabotropic-G\textsubscript{q} protein coupled receptors [25–27]. Furthermore, the intracellular Ca\textsuperscript{2+} concentration generated by ATP in the presence of PPADS (Figure 5A, dashed line) was at least three times lower than that induced by ATP alone (Figure 5A, solid line). In the absence of extracellular Ca\textsuperscript{2+}, ATP was also able to induce intracellular Ca\textsuperscript{2+} mobilization, resulting from the direct action of inositol 1,4,5-trisphosphate (InsP\textsubscript{3}) on the endoplasmic reticulum stores. Addition of PPADS did not change this response (Figure 5B). Figure 5C illustrates C2C12 myotubes Ca\textsuperscript{2+} response induced by ATP in the cells pretreated (Figure 5C, dashed line), or not pretreated (Figure 5C, solid line) with PPADS. As it is shown, ATP, both in the absence and the presence of PPADS generated similar elongated Ca\textsuperscript{2+} response, characteristic to metabotropic receptors and P2X receptors antagonist (PPADS) did not influence this process (Figure 5C, solid and dashed lines). ATP-induced Ca\textsuperscript{2+} response was much weaker in myotubes than in myoblasts (Figure 5). Moreover, similar Ca\textsuperscript{2+} response in myotubes was induced by UTP (data not shown).

α, β-methylene ATP (100–600 μM), a P2X\textsubscript{1}/P2X\textsubscript{3} agonist produced no Ca\textsuperscript{2+} response (data not shown) what is coherent with the lack of mRNA for these receptors both in myoblasts and myotubes. Figure 5D shows the effect of 100-μM 3′-0(4-benzoyl)benzoyl ATP (BzATP) application on myoblasts and myotubes calcium response. BzATP is a specific agonist of the P2X\textsubscript{7} receptor, which is 10–100 times more sensitive to this ATP analog then to ATP itself [14]. While myoblasts clearly responded to addition of BzATP, myotubes did not react at all. The presence of calcium response to BzATP in myoblasts is in agreement with the presence of P2X\textsubscript{7} mRNA in those cells whereas in myotubes, the P2X\textsubscript{7} receptor seemed not to be coupled to calcium signal. It is worthy adding that response to BzATP was so weak that we have had to change the vertical axis scale to show changes, while all other plots on this figure (Figure 5A–C) have the same scale to make comparison of responses easier.

Discussion

In this study we investigated the presence of the different P2Y receptor subunits on the mouse myoblast satellite cell line, C2C12, and on myoblasts differentiated to myotubes, 7 days after transfer into differentiating medium. Using RT-PCR we have demonstrated that C2C12 myoblasts did express a wide range of P2Y receptors – P2Y\textsubscript{1}, P2Y\textsubscript{2}, P2Y\textsubscript{4}, P2Y\textsubscript{6} and P2Y\textsubscript{12}. After differentiation to myotubes, P2Y\textsubscript{1}, P2Y\textsubscript{4}, P2Y\textsubscript{6} and P2Y\textsubscript{12} receptors mRNA expression distinctly decreased. In contrast, the P2Y\textsubscript{2} receptor mRNA expression was not affected in myotubes. Differentiation into myotubes did not change the level of P2X\textsubscript{4}, P2X\textsubscript{5} and P2X\textsubscript{7} mRNA expression whereas P2X\textsubscript{2} mRNA absent in myoblasts appears in myotubes.

These results are generally similar to those presented by Ryten et al. [4], who used primary cultures of satellite skeletal myoblasts maintained in the medium with 5% HS to form myotubes. Similarly to our data, the authors showed the presence of the P2X\textsubscript{3} receptor in myoblasts and myotubes, whereas the P2X\textsubscript{2} receptor was absent in myoblasts and appeared in myotubes only from fifth day of differentiation. The authors also found that myoblasts contained the P2Y\textsubscript{1} receptor which disappeared after 5 days of differentiation, whereas in our experiments the level of its expression was only lowered. The difference is the P2Y\textsubscript{4} receptor, which appeared only after plating in Ryten experiments [4], while in our results was present in myoblasts and diminished in myotubes. At all these time points, the P2Y\textsubscript{2} receptor was not detectable in Ryten data whereas in our data P2Y\textsubscript{2} mRNA both in myoblasts and myotubes was always the most abundant one. Moreover, in C2C12 myotubes, Henning et al. [28, 29] demonstrated the activity of this metabotropic P2Y\textsubscript{2} receptor. Thus, some discrepancy between our results and the results of Ryten et al. [4] may be caused by the different origin of the cultured cells. Nevertheless, both papers demonstrated dynamic expression of P2Y and P2X receptors.

ERK1/2 signalling cascade have been implicated in myoblast proliferation [30, 31]. The present study shows that the treatment of C2C12 myoblasts with ATP, ADP, 2MeSADP, UTP and UDP caused a rapid and transient increase in the level of phosphorylated ERK1/2. This process was fully Ca\textsuperscript{2+} dependent. Application of ATP to myoblasts caused also a significant increase in ERK1/2 phosphorylation. Furthermore, the effect of ATP on ERKs activation in myoblasts may be inhibited by preapplication of PPADS, known as an antagonist of P2X\textsubscript{2} and P2X\textsubscript{5} receptors but not P2X\textsubscript{4} and P2Y\textsubscript{2} receptors [14, 16, 19, 32]. Such effect of PPADS was not observed in myotubes. Hence, these results suggest that although the P2Y\textsubscript{2} receptor is expressed in C2C12 myoblast cells, P2X\textsubscript{4} receptors is primarily responsible for the observed ATP effects since P2X\textsubscript{2} is absent in myoblasts. On the other hand the myotubes are not PDDS sensitive even though both P2X\textsubscript{2} and P2X\textsubscript{3} receptor mRNA is present in those cells. Since ERK 1/2 activation is strongly dependent on Ca\textsuperscript{2+} cations [33], these results could suggest that in myotubes P2X receptors might be permeable to some other than Ca\textsuperscript{2+} cations [33].

These conclusions are strongly supported by the difference in the kinetic of ATP-evoked Ca\textsuperscript{2+} responses examined in C2C12 myoblasts in the presence and absence of PPADS, or extracellular Ca\textsuperscript{2+}. In the presence of extracellular Ca\textsuperscript{2+} and absence of PPADS, the high and rapid Ca\textsuperscript{2+} response was most probably generated by P2X receptors, particularly by the P2X\textsubscript{3} receptor. In general, the Ca\textsuperscript{2+} influx generated by ligand-gated ionotropic receptors is much quicker than that mediated by metabotropic-G\textsubscript{q} protein coupled receptors [34]. In addition, the rapid increase in
intracellular Ca\(^{2+}\) concentration can inhibit InsP\(_3\) receptor and stops the metabotropic receptor action [35, 36]. Thus, one can expect that when ATP stimulates a cell that contains P2X and P2Y receptors, a P2X, no P2Y receptor will be primarily involved in Ca\(^{2+}\) mobilization. On the other hand, when P2X receptors are antagonized with PPADS, or when the cells are examined in the absence of extracellular Ca\(^{2+}\), then the P2Y\(_2\) receptor activity may still lead to the increase in the intracellular Ca\(^{2+}\) concentration. Such ATP-induced Ca\(^{2+}\) response difference has been observed herein.

In C2C12 myotubes, ATP generated similar, however very weak Ca\(^{2+}\) response in the presence and absence of PPADS, and PPADS did not reduce ATP-induced ERKs activation. These results suggest the lack of P2X receptor activity in these cells. Similarly, in developing chick skeletal muscle, P2X\(_3\) and P2X\(_6\) receptors were only expressed at early stages of skeletal muscle development. Their expression disappeared immediately before the stage at which fusion of myoblast to form myotubes occurred [11]. Furthermore, as we have already mentioned, in C2C12 myotubes, Henning et al. [28, 29] demonstrated the presence of the metabotropic P2Y\(_2\) receptor, responding to ATP and UTP and causing a biphasic rise in intracellular Ca\(^{2+}\) concentration by the release of Ca\(^{2+}\) from the internal stores and activation of Ca\(^{2+}\) entry from the extracellular space.

Thus, it seems that during C2C12 myoblast developing, P2X receptors are the first to be expressed and first to be down regulated. While in C2C12 myoblasts an ATP-sensitive P2X\(_3\) receptor is primarily responsible for Ca\(^{2+}\) mobilization and ERK1/2 activation, in myotubes this role may play the P2Y\(_2\) receptor, which mRNA is still expressed in myotubes. Our data agree with thesis that P2X\(_3\) receptor plays the crucial role in regulation of shift between myoblast proliferation and differentiation [4, 5]. However, we should be aware that C2C12 cell line never completely differentiates. Therefore P2Y receptors may be still active in those cells while in primary lines they do disappeared during further differentiation into myofibers [22]. It is also worth adding that we have recently shown that serum withdrawal for 48 h had effects on glioma C6 cells morphology, which changed from fibroblast-like to astrocyte-like appearance. Simultaneously with this differentiation-like process, the P2Y\(_1\) mRNA expression strongly decreased and the P2Y\(_{12}\) mRNA slightly increased [32, 37]. Hence, we do believe that changing pattern of expression and activity of purinergic receptors may be involved in cell differentiation control and should be further studied in various cell types.

Acknowledgements

We thank Prof. Jerzy Moraczewski (Warsaw University, Warsaw, Poland) for the kind gift of a murine, C2C12 myoblast cell line. This study was supported by a grant from the State Committee for Scientific Research (KBN, Poland) to the Nencki Institute of Experimental Biology and Grants KBN No. 3 PO5A 119 22 and 3 PO4A 012 24.

References

1. Perry RL, Rudnicki MA. Molecular mechanisms regulating myogenic determination and differentiation. Front Biosci 2000; 5: D750–D769.
2. Seale P, Rudnicki MA. A new look at the origin, function, and “stem-cell” status of muscle satellite cells. Dev Biol 2000; 218(2): 115–24.
3. Hawke TJ, Garry DJ. Myogenic satellite cells: Physiology to molecular biology. J Appl Physiol 2001; 91(2): 534–51.
4. Ryten M, Yang SY, Dunn PM et al. Purinoceptor expression in regenerating skeletal muscle in the mdx mouse model of muscular dystrophy and in satellite cell cultures. FASEB J 2004; 18(12): 1404–6.
5. Ryten M, Dunn PM, Neary JT, Burnstock G. ATP regulates the differentiation of mammalian skeletal muscle by activation of a P2X5 receptor on satellite cells. J Cell Biol 2002; 158(2): 345–55.
6. Cseri J, Szappanos H, Szigeti GP et al. A purinergic signal transduction pathway in mammalian skeletal muscle cells in culture. Pfugers Arch 2002; 443(5): 731–8.
7. Henning RH, Nelemans A, van den Akker J, den Hertog A. The nucleotide receptors on mouse C2C12 myotubes. Br J Pharmacol 1992; 106(4): 853–8.
8. Campbell JS, Wenderoth MP, Haushka SD, Krebs EG. Differential activation of mitogen-activated protein kinase in response to basic fibroblast growth factor in skeletal muscle cells. Proc Natl Acad Sci USA 1995; 92(3): 870–4.
9. Weyman CM, Wolfman A. Mitogen-activated protein kinase kinase (MEK) activity is required for inhibition of skeletal muscle differentiation by insulin-like growth factor 1 or fibroblast growth factor 2. Endocrinology 1998; 139(4): 1794–800.
10. Conejo R, Lorenzo M. Insulin signaling leading to proliferation, survival, and membrane ruffling in C2C12 myoblasts. J Cell Physiol 2001; 187(1): 96–108.
11. Meyer MP, Groschel-Stewart U, Robson T, Burnstock G. Expression of two ATP-gated ion channels, P2X5 and P2X6, in developing chick skeletal muscle. Dev Dyn 1999; 216(4–5): 442–9.
12. Meyer MP, Clarke JD, Patel K et al. Selective expression of purinoceptor cP2Y1 suggests a role for nucleotide signalling in development of the chick embryo. Dev Dyn 1999; 214(2): 152–8.
13. Ryten M, Hoebertz A, Burnstock G. Sequential expression of three receptor subtypes for extracellular ATP in developing rat skeletal muscle. Dev Dyn 2001; 221(3): 331–41.
14. Ralevic V, Burnstock G. Receptors for purines and pyrimidines. Pharmacol Rev 1998; 50(3): 413–92.
15. Abbracchio MP, Burnstock G. Purinoceptors: Are there families of P2X and P2Y purinoceptors? Pharmacol Ther 1994; 64(3): 445–75.
16. Boarder MR, Hourani SM. The regulation of vascular function by P2Y receptors: Multiple sites and multiple receptors. Trends Pharmacol Sci 1998; 19(3): 99–107.
17. Abbracchio MP, Burnstock G. Purinergic signalling: Pathophysiological roles. Jpn J Pharmacol 1998; 78(2): 113–35.
18. Hollopeter G, Jantzen HM, Vincent D et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001; 409(6817): 202–7.
19. Czajkowski R, Baranska J. Cross-talk between the ATP and ADP nucleotide receptor signalling pathways in glioma C6 cells. Acta Biochim Pol 2002; 49(4): 877–89.
20. Zhang FL, Luo L, Gustafson E et al. P2Y(13): Identification and characterization of a novel Galpha{i}-coupled ADP receptor from human and mouse. J Pharmacol Exp Ther 2002; 301(2): 705–13.
21. Choi RC, Man ML, Ling KK et al. Expression of the P2Y1 nucleotide receptor in chick muscle: Its functional role in the regulation of acetylcholinesterase and acetylcholine receptor. J Neurosci 2001; 21(23): 9224–34.
22. Cheung KK, Ryten M, Burnstock G. Abundant and dynamic expression of G protein-coupled P2Y receptors in mammalian development. Dev Dyn 2003; 228(2): 254–66.

23. Grynkiewicz G, Poenie M, Tsien RY. A new generation of Ca\(^{2+}\) indicators with greatly improved fluorescence properties. J Biol Chem 1985; 260(6): 3440–50.

24. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248–54.

25. Berridge MJ. Capacitative calcium entry. Biochem J 1995; 312(Pt 1): 1–11.

26. Putney JW Jr, Bird GS. The inositol phosphate–calcium signaling system in nonexcitable cells. Endocr Rev 1993; 14(5): 610–31.

27. Baranska J, Przybylek K, Sabala P. Capacitative calcium entry. Glioma C6 as a model of nonexcitable cells. Pol J Pharmacol 1999; 51(2): 153–62.

28. Henning RH, Duin M, den Hertog A, Nelemans A. Characterization of P2-purinoceptor mediated cyclic AMP formation in mouse C2C12 myotubes. Br J Pharmacol 1993; 110(1): 133–8.

29. Henning RH, Duin M, den Hertog A, Nelemans A. Activation of the phospholipase C pathway by ATP is mediated exclusively through nucleotide type P2-purinoceptors in C2C12 myotubes. Br J Pharmacol 1993; 110(2): 747–52.

30. Bennett AM, Tonks NK. Regulation of distinct stages of skeletal muscle differentiation by mitogen-activated protein kinases. Science 1997; 278(5341): 1288–91.

31. Jones NC, Fedorov YV, Rosenthal RS, Olwin BB. ERK1/2 is required for myoblast proliferation but is dispensable for muscle gene expression and cell fusion. J Cell Physiol 2001; 186(1): 104–15.

32. Czajkowski R, Banachewicz W, Ilnytska O et al. Differential effects of P2Y1 and P2Y12 nucleotide receptors on ERK1/ERK2 and phosphatidylinositol 3-kinase signalling and cell proliferation in serum-deprived and nonstarved glioma C6 cells. Br J Pharmacol 2004; 141(3): 497–507.

33. Henning RH. Purinoceptors in neuromuscular transmission. Pharmaco- col Ther 1997; 74(1): 115–28.

34. Berridge MJ. Inositol trisphosphate and calcium signalling. Nature 1993; 361(6410): 315–25.

35. Worley PF, Baraban JM, Supattapone S et al. Characterization of inositol trisphosphate receptor binding in brain. Regulation by pH and calcium. J Biol Chem 1987; 262(25): 12132–6.

36. Taylor CW, Laude AJ. IP3 receptors and their regulation by calmodulin and cytosolic Ca\(^{2+}\). Cell Calcium 2002; 32(5–6): 321–34.

37. Baranska I, Czajkowski R, Sabala P. Cross-talks between nucleotide receptor-induced signaling pathways in serum-deprived and non-starved glioma C6 cells. Adv Enzyme Regul 2004; 44: 219–232.